Targeted pill vs. chemo for EGFR-mutant lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new targeted pill (YK-029A) versus standard chemotherapy as the first treatment for advanced lung cancer with a specific EGFR mutation. It aims to see if the targeted pill works better and has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your lung cancer is non-squamous and has spread to other parts of the body (stage IV) or cannot be removed with surgery.
- Your cancer has a specific mutation called EGFR exon 20 insertion.
- You have not had previous treatment for advanced or metastatic lung cancer.
- You are able to take care of yourself (up and about) and have a life expectancy of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new targeted pill called TY-9591 combined with chemotherapy as a first treatment for advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination works better than the current standard of care.
This study tests an oral pill (DZD9008) that targets a specific genetic change in lung cancer called EGFR. If you have this mutation, the drug may shrink your tumor or slow its growth, especially if other treatments have stopped working or caused side effects.
This study tests an oral pill (BPI-361175) for people with advanced non-small cell lung cancer that has specific EGFR mutations, especially when standard EGFR-targeted treatments are no longer working. The goal is to see if it can shrink tumors or slow growth.
This trial compares a new targeted therapy pill (firmanertinib) to standard chemotherapy in people with advanced non-small cell lung cancer whose tumors have a specific EGFR mutation (PACC or L861Q). If you haven't had treatment for advanced disease and your cancer matches these mutations, this study may offer a more convenient oral option.
This trial is testing a new targeted pill for people with EGFR-positive non-small cell lung cancer. It's designed for those whose cancer has grown after other treatments, and it works by blocking a specific protein that helps the cancer grow.
This study tests a new pill called PLB1004 for people whose lung cancer has a specific EGFR mutation (exon 20 insertion). It is for those who have not yet had any treatment for their advanced cancer.
Hear when a new Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.